December 20, 2018

    BCN Peptides has been a key GAPVAC European Consortium member that has performed the first-in-human Clinical trial of a Personalized Therapeutic Vaccine to treat Glioblastoma. BCN Peptides role was the Manufacture of of the GMP Peptides Library used for the Vaccine production. We are proud to announce that the demonstration of the proof-of-concept for the Personalized approach has been published by Nature on date 19th December, 2018 (DOI 10.1038/s41586-018-0810-y). For more information you can download the GAPVAC Press release. BCN Peptides is completely committed with the growth of Personalized Medicine, as we consider this is a strategic therapy for the treatment of oncology patients in the near future. For this reason we are actively developing solutions for the challenges that Individualized Drug production represents for the Pharma Industry. GAPVAC press release_Nature

  • BCN Peptides iniciates a collaboration with IDP-Pharma

    April 3, 2017

    BCN Peptides supports IDP-Pharma in the development of a new chemical entity aimed to treat Multiple Myeloma.

    The collaborative project has been granted with funds from the European Union FEDER via ACCIO and its programme”Nuclis d’Innovació Tecnológica”.


  • BCN Peptides R&D on Lysosomal Storage Diseases

    March 20, 2017

    BCN Peptides  is working in a research program having as therapeutic target  Lysosomal Storage diseases, a group of  rare inherited metabolic disorders that result from defects in lysosomal function.

    The project, enclosed in “Nuclis d’Innovació Tecnològica” program from ACCIÒ, is cofinanced with the European Union FEDER funds.